Assessment of Advanced Liver Fibrosis and the Risk for Hepatic Decompensation in Patients With Congestive Hepatopathy

Alexander Lemmer, Lisa B. VanWagner, Daniel Ganger – 19 April 2018 – Congestive hepatopathy (CH) arises from chronically elevated right‐sided heart pressures transmitted to the liver by passive venous congestion. Over time, CH can lead to hepatic bridging fibrosis, decompensated cirrhosis, and hepatocellular carcinoma.

Assessment of Advanced Liver Fibrosis and the Risk for Hepatic Decompensation in Patients With Congestive Hepatopathy

Alexander Lemmer, Lisa B. VanWagner, Daniel Ganger – 19 April 2018 – Congestive hepatopathy (CH) arises from chronically elevated right‐sided heart pressures transmitted to the liver by passive venous congestion. Over time, CH can lead to hepatic bridging fibrosis, decompensated cirrhosis, and hepatocellular carcinoma.

De Novo Hepatocellular Carcinoma Among Liver Transplant Registrants in the Direct Acting Antiviral Era

Allison J. Kwong, W. Ray Kim, Jennifer A. Flemming – 19 April 2018 – The risk of hepatocellular carcinoma (HCC) in patients with hepatitis C virus (HCV) receiving direct acting antivirals (DAAs) has been debated. This study aims to describe the incidence of HCC among patients listed for liver transplantation (LT) in the DAA era. Individuals with cirrhosis listed for LT from January 2003 to December 2015 were identified using the Scientific Registry for Transplant Recipients database. Patients with HCC at listing or HCC exception within 180 days were excluded.

Cirrhotic Cardiomyopathy After Transplantation: Neither the Transient Nor Innocent Bystander

Manhal Izzy, Jae Oh, Kymberly D. Watt – 19 April 2018 – Cirrhotic cardiomyopathy in end‐stage liver disease is currently characterized by blunted contractile systolic response to stress with or without diastolic dysfunction in the absence of known heart disease. Since the establishment of the diagnostic criteria of cirrhotic cardiomyopathy in 2005, there have been multiple studies regarding its pathophysiology and pretransplant clinical course. The data regarding the post‐transplant course of this entity are sparse.

Metabolic risk factors are associated with non‐hepatitis B non‐hepatitis C hepatocellular carcinoma in Taiwan, an endemic area of chronic hepatitis B

Shiu‐Feng Huang, Il‐Chi Chang, Chih‐Chen Hong, Tseng‐Chang Yen, Chao‐Long Chen, Cheng‐Chung Wu, Cheng‐Chung Tsai, Ming‐Chih Ho, Wei‐Chen Lee, Hsien‐Chung Yu, Ying‐Ying Shen, Hock‐Liew Eng, John Wang, Hui‐Hwa Tseng, Yung‐Ming Jeng, Chau‐Ting Yeh, Chi‐Ling Chen, Pei‐Jer Chen, Yun‐Fan Liaw – 18 April 2018 – Metabolic risk factors, such as obesity, fatty liver, high lipidemia, and diabetes mellitus are associated with increased risk for nonviral hepatocellular carcinoma (HCC); however, few nonviral HCC studies have stratified patients according to underlying etiologies.

Subscribe to